To include your compound in the COVID-19 Resource Center, submit it here.

Agios submits NDA for ivosidenib to treat relapsed or refractory AML

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) submitted

Read the full 50 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE